STAT’s biotech podcast The Readout Loud covers the latest in life sciences news with a single episode split into two segments. One segment deals with a court ruling on foreign student visas, while the other focuses on new data from Definium Therapeutics in the psychedelics field.
The Visa Case for Researchers
Jonathan Wosen, a STAT reporter, and Fanta Av, executive director of NAFSA: Association of International Educators, joined the podcast to discuss a recent court decision around foreign student visas. Many researchers are still considering leaving the United States for opportunities elsewhere, even with the reprieve. The episode explores whether the legal shift will affect those plans, or if the damage has already been done.
Definium’s Psychedelics Data
The second half of the episode focuses on new data from Definium Therapeutics, which is developing drugs in the emerging psychedelics sector. The company’s results are being weighed against what they mean for the broader field.
The episode does not state explicitly what the Definium data shows, but the framing suggests the company’s results are being used to gauge the health of the psychedelics sector as a whole.
Who Runs The Readout Loud
The podcast is co-hosted by three reporters with distinct beats:
- Adam Feuerstein, senior writer and biotech columnist, also writes Adam’s Biotech Scorecard
- Elaine Y. W. Chen, STAT reporter covering obesity treatments, drug payment models and FDA changes, co-writes The Readout newsletter
- Allison DeAngelis, covering hot startups and their financiers
How to Listen
The episode is available on Apple Podcasts, Spotify and other podcast platforms.
What the Episode Does Not Cover
The episode description does not specify which Definium data was presented, nor does it name which segment covered the visa ruling in full. Listeners interested in the specifics of Definium’s trial results or the court’s reasoning will need to listen directly.
The Bigger Picture
The visa case is not a standalone story. It sits inside a larger pattern of international researchers reconsidering the United States as a base of operations. The Definium data, meanwhile, is part of a growing wave of clinical results from companies pursuing psychedelic compounds as therapeutics.
Taken together, the two segments offer a snapshot of the forces shaping American medical research today: one legal, one scientific, and both with implications far beyond their immediate subjects.
Why This Matters
The visa ruling could change which researchers are willing to stay in the United States. The Definium data could shape investor appetite for psychedelic stocks. Both threads feed into the same question: what kind of research ecosystem will the country have in ten years.
The episode does not settle that question. It presents the pieces of the puzzle and lets listeners draw their own conclusions.
The Readout Loud airs weekly and covers the full range of biotech news, from FDA policy to startup funding to clinical trial data. This episode, with its split focus on immigration law and psychedelic science, shows the variety of topics the show handles.
| Segment | Topic |
|---|---|
| Part 1 | Court decision on foreign student visas |
| Part 2 | Definium’s psychedelics data |
The two segments are distinct in subject but share a common thread: both deal with the global forces shaping American medical research.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.